Last reviewed · How we verify
Minocycline HCl
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Bacterial infections (respiratory, urinary, skin, soft tissue), Acne vulgaris, Periodontal disease (subgingival delivery formulation).
At a glance
| Generic name | Minocycline HCl |
|---|---|
| Also known as | antibiotic, Meiman, Periocline |
| Sponsor | OraPharma |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Dermatology; Periodontal Disease |
| Phase | FDA-approved |
Mechanism of action
Minocycline HCl is a second-generation tetracycline antibiotic that penetrates bacterial cells and binds to the 30S ribosomal subunit, blocking aminoacyl-tRNA from entering the A site and preventing peptide bond formation. This inhibition of protein synthesis is bacteriostatic, stopping bacterial growth and allowing the immune system to clear the infection. Minocycline has enhanced lipophilicity compared to first-generation tetracyclines, allowing superior tissue penetration and oral bioavailability.
Approved indications
- Bacterial infections including acne, respiratory tract infections, urinary tract infections, and other susceptible gram-positive and gram-negative infections
- Periodontal disease (subantimicrobial-dose formulation)
Common side effects
- Photosensitivity
- Nausea and vomiting
- Dizziness or vertigo
- Esophageal irritation
- Vaginal candidiasis
- Rash
Key clinical trials
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Minocycline in Stroke Study at Maimonides (PHASE2, PHASE3)
- Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Topical Minocycline for CARP (EARLY_PHASE1)
- Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
- Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minocycline HCl CI brief — competitive landscape report
- Minocycline HCl updates RSS · CI watch RSS
- OraPharma portfolio CI